UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

November 10, 2026
Date of Report (date of earliest event reported)

Prime Medicine, Inc.

(Exact name of registrant as specified in its charter)

Delaware	**001-41536**	**84-3097762**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

60 First Street
Cambridge, MA 02141
(Address of principal executive offices and zip code)

(617) 465-0013
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, par value $.00001 per share	PRME	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On November 10, 2026, Prime Medicine, Inc. (the "Company") announced that the preliminary unaudited estimates of its cash, cash equivalents, and short-term investments were approximately $61.2 million as of September 30, 2026, excluding its restricted cash of approximately $13.7 million. The Company has not yet completed its quarter-end financial close process for the quarter ended September 30, 2026. The foregoing information is based on preliminary unaudited information and management estimates as of and for the quarter ended September 30, 2026, is not a comprehensive statement of the Company's financial results, and is subject to completion of the Company's financial closing procedures. There can be no assurance that the Company's actual financial results as of September 30, 2026 will not differ from these estimates, including as a result of the completion of the Company's final adjustments, and other developments arising between the date of this filing and the time that the Company's financial results for such period are finalized, and any such changes could be material.

These preliminary unaudited estimates have been prepared by, and are the responsibility of, the Company's management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. These estimates should not be viewed as a substitute for interim financial statements prepared in accordance with accounting principles generally accepted in the United States and they are not necessarily indicative of the results to be achieved in any future period. Complete results as of September 30, 2026 will be included in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. The Company assumes no duty to update these preliminary estimates, except as required by law.

The information contained in Item 2.02 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events

On November 10, 2026, the Company posted an updated corporate presentation to its website at https://investors.primemedicine.com/news-events. A copy of the updated corporate presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Reference to the Company's website is for inactive textual reference only and the content of the website should not be deemed incorporated by reference into this Current Report on Form 8-K.

Cautionary Note Regarding Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the Company's preliminary unaudited estimates of its cash, cash equivalents, and short-term investments as of September 30, 2026. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements contained in this Current Report on Form 8-K are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form 8-K. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and any of its subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Corporate Presentation, dated November 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 10, 2026

Prime Medicine, Inc.


By: /s/ Allan Reine

Name: Allan Reine, M.D.

Title: Chief Executive Officer

prime medicine_

Delivering on the promise of
Prime Editing



Corporate Presentation


November 2026

Forward Looking Statements

This presentation contains forward-looking statements of Prime Medicine, Inc. ("Prime", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements contain information about our current and future prospects and our operations, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, projects and plans are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “hope,” “intend,” “may,” “might,” “objective,” “opportunity,” “plan,” “predict,” “positioned,” “possible,” “potential,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, express or implied statements about Prime’s beliefs and expectations regarding: the potential of Prime Editing to correct the causative mutations of diseases, including Wilson disease ("WD"), Alpha-1 Antitrypsin Deficiency (“AATD”), chronic granulomatous disease ("CGD"), and Cystic Fibrosis; the continued development and advancement of PM577a and PM647, including the ongoing Phase 1/2 trial of PM577a, planned Phase 1/2 trial of PM647, and the timing of initial data for both in 2027; the ongoing regulatory engagement with the FDA on PM359 and the outcomes of such engagement, including the planned submission of a BLA filing in the first half of 2027 and our ability to obtain regulatory approval for, and commercially launch, PM359 in CGD; the initiation, timing, progress and results of our research and development programs, preclinical studies and future clinical trials, including the release of data related thereto; the significance of data from our Phase 1/2 trial of PM359; the safety profile of Prime Editing, our modular LNP, and our programs; the timing of, and our ability to achieve, clinical validation and sustained, long-term value creation; the modularity of the Prime Editing platform and our LNP and the benefits thereof; the 2025 agreement with the Cystic Fibrosis Foundation, its expanded funding pursuant thereto, and the intended and potential benefits thereof; the collaboration with Bristol Myers Squibb and the intended and potential benefits thereof, including the receipt of potential milestone and royalty payments from commercial product sales, if any; our expectations regarding the breadth of Prime Editing, including the potential of Prime Editing to address approximately 90% of genetic diseases and to address non-genetic diseases; the continued development and optimization of various delivery systems, including our universal liver-targeted LNP delivery approach; the scope of protection we are able to establish and maintain for intellectual property rights covering our Prime Editing technology; the implementation of our strategic plans for our business, programs and technology, including our ability to maintain collaborations or strategic relationships and identify and enter into future license agreements and collaborations; regulatory developments in the United States and foreign countries; developments related to our competitors and our industry; our estimates of our expenses, capital requirements, and needs for additional financing; our ability to continue as a going concern; and our expectations regarding the anticipated timeline of our cash runway and future financial performance. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make due to a number of risks and uncertainties. These and other risks, uncertainties and important factors are described in the section entitled "Risk Factors" in our most recent Annual Report on Form 10-K, as well as any subsequent filings with the SEC. Any forward-looking statements represent our views only as of the date of this presentation and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, the occurrence of certain events or otherwise subject to any obligations under applicable law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. No representations or warranties (express or implied) are made about the accuracy of any such forward-looking statements.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

Prime Editing: Emerging as the Predominant Gene Editing Technology



Gene editing **permanently corrects** genetic alterations

Prime Editing is the **most versatile** gene editing technology


Prime Medicine's **IP position** covers any permutation of Prime Editing

Prime Editing **does not cause double-strand breaks or bystander edits**

New regulatory models pave way for **platform-based approvals**

Clinical data with Prime Editors support **curative potential**

Prime Medicine is Strategically Delivering on the Promise of Prime Editing



DISCIPLINED CLINICAL DEVELOPMENT, MAXIMIZE PLATFORM IMPACT AND ENSURE ACCESS TO BREAKTHROUGH THERAPIES

Near-Term, Focused Execution Positions Prime Medicine to Capitalize on the Full Potential of Prime Editing


prime_ medicine

Achieved and Anticipated Milestones

	2026	2027
WILSON DISEASE	✓PM577a CTA and IND cleared ✓Initiate clinical trial • Advance follow-on Prime Editors for other common mutations	• Announce PM577a initial clinical data • Capitalize on platform modularity vis-a-vis additional common mutations (e.g., R778L in Asia among other pathogenic variants)
AATD	✓PM647 IND cleared • Initiate clinical trial	• Announce PM647 initial clinical data
OTHER	• Progress towards a BLA filing for CGD • Share *in vivo* proof-of-concept data in CF • Expand pipeline within priority focus areas and beyond	• Submit BLA for PM359 in CGD

Secure multiple additional strategic partnerships to accelerate our pipeline and bolster our financial resources


Prime Medicine's Pipeline: Focused on Value Creating Opportunities



Prime Medicine is identifying opportunities to expand the reach of Prime Editing either via organic growth around its liver franchise and / or business development

[1] In January 2024 and July 2025, Prime entered into agreements with the CF Foundation for up to $15 million and $24 million, respectively, to support development of Prime Editors for Cystic Fibrosis.
[2] In September 2024, Prime entered into a strategic research collaboration and license agreement with Bristol Myers Squibb to develop and commercialize multiple *ex vivo* T cell products in immunology and oncology.
LNP = lipid nanoparticle; AAV = adeno-associated virus; CGD = chronic granulomatous disease

We Plan to Leverage the Versatility of Prime Editing to Address a Range of Diseases Across Target Tissues



Deletion / Insertion Correction
p47 Chronic Granulomatous Disease (CGD)

Point Mutation Correction
Wilson Disease, Alpha-1 Antitrypsin Deficiency


Hotspot Correction
Cystic Fibrosis, Retinitis Pigmentosa (RHO adRP)

Repeat Excision
Repeat expansion diseases


Targeted Full Gene Insertion (PASSIGE™)
CAR-T, Cystic Fibrosis

Prime Editing is designed with a wide range of genome editing capabilities and the potential to make edits of any size, from small base pair swaps to large, multi-kilobase insertions or inversions

Modular Prime Editing Platform Flywheel Effect: Industrialized Engine is Reused Across Programs



Prime Medicine Holds Extensive, Foundational Intellectual Property for Prime Editing Technologies



CRISPR-Cas Enzyme
Any programmable nuclease to specifically identify and cut DNA sequences

Guide RNA
Engineered RNAs that locate the exact editing site and provide the template for transcription

Reverse Transcriptase
Converts RNA into complementary DNA

Any combination or permutation of a **CRISPR-Cas enzyme**, template **Guide RNA** with a **Reverse Transcriptase** is **Prime Editing** and is covered by our extensive patent estate

Prime Medicine holds 10 U.S. and 21 ex-U.S. issued patents in an extensive patent estate that protects its breakthrough Prime Editing platform, delivery technologies and therapeutics

Liver



Prime Medicine's Initial Liver Franchise: Aspiring to Cure Two of the Largest Genetic Liver Diseases, Enabled by Platform Modularity

prime_ medicine

PM577: Wilson Disease

Opportunity (Patients: All Mutations)

>20,000	US and EU
7,500-15,000+	Japan

Clinical trial initiated; data anticipated 2027

Initial focus on H1069Q mutation

PM647: AATD

Opportunity (Patients)

200,000	US and EU
20,000-30,000	Diagnosed*

IND cleared; data anticipated 2027

Plan to leverage key learnings, regulatory frameworks and manufacturing synergies from PM577a to accelerate efforts and reduce costs for other Wilson Disease mutations, AATD and future follow-on liver programs


WD = Wilson Disease; AATD = Alpha-1 Antitrypsin Deficiency; IND = investigational new drug; CTA = clinical trial application
*Prime Medicine estimate

Proprietary LNP-Formulated Prime Editor is a Complex Multi-Component Drug Product Designed to Support Current and Future Liver Programs

prime_ medicine


LNP Modularity:

Majority of components in the LNP are the same across liver programs



Ionizable Lipid	Nucleic acid encapsulation and endosomal escape
Helper Lipid	Stabilize and improve LNP pharmacokinetics, facilitate membrane fusion and endosomal escape
PEG Lipids	Control particle size and stability, stealth coating reduces serum interactions and increases half-life
Cholesterol	Improve intracellular delivery, increase LNP stability
Targeting Ligand	Proprietary GalNAc formulation to improve biodistribution of LNPs to hepatocytes
PE mRNA	Prime editor enzyme
pegRNA	pegRNA is disease and mutation specific
ngRNA	ngRNA is disease and mutation specific; usage is dependent on the Prime Editing strategy applied

Wilson Disease



Advancing Prime Editors for Wilson Disease: Disease Overview

Large genetically defined disease well suited for Prime Editing

Disease Severity and Opportunity


- Common liver and systemic disease presenting in teens to 20s
- Leads to liver failure, neurocognitive decline and premature death
- Greater than 20,000 patients in US and Europe, 30-50% harboring H1069Q mutation
- 7,500 – 15,000+ patients in Japan, R778L is the predominant mutation in the Asian population

Unmet Need

- No approved disease modifying therapies
- Current standard of care aims to prevent copper accumulation; options include chelating agents and low copper diet
- Liver transplantation is last resort option in most severe patients


Human Biology

- Autosomal recessive due to loss of function mutations in ATP7B
- Affects copper homeostasis, leading to toxic accumulation of copper in liver and brain



Prime Medicine's Wilson Disease Programs Have Potential to Address Large Commercial Opportunity


- **Six most common mutations account for up to 26,000 patients** in addressable markets (US, Europe, Japan) with unique geographic mutational distribution; incidence rate of approximately 300 new patients per year
- **Consistency in disease presentation and management** across mutations and key markets enables Prime Medicine to establish an anchor with PM577a (H1069Q) to provide leverage and read-through to other mutations




Prime Editors Efficiently and Precisely Corrected the Two Most Prevalent Disease-Causing Mutations in Wilson Disease

prime_ medicine

Efficient correction of the H1069Q and R778L mutations in fully humanized mouse models



No detectable off-target editing identified in patient-derived cells for PM577a



Prime Editors delivered with Prime Medicine's universal liver LNP administered at clinically relevant doses


LNP = lipid nanoparticle

PM577a Efficiently Corrected the H1069Q Mutation and Restored Wild-Type Copper Concentration at Multiple Doses in Preclinical Studies


prime_ medicine

~45% editing restored copper levels to near wild-type levels


Precise correction of ATP7B p.H1069Q in mice



Increase in wild-type ATP7B protein expression*




Liver copper restored to wild-type levels*



*ATP7B protein expression and liver copper measurements taken at 4 weeks

Prime Edited Mice Challenged with Radiolabeled Copper Demonstrated Normal Copper Metabolism At Multiple Doses



Copper challenge and PET imaging performed 4 weeks post PE treatment, PET imaging performed 24hrs post copper challenge

PM577a Clinical Trial Overview

Trial Overview


Design
Phase 1/2, open-label

Population
Adults and adolescents with Wilson Disease and at least one ATP7B p.H1069Q allele

Treatment
Single IV infusion of PM577a

Primary Endpoints
Safety and tolerability

Key Secondary Endpoints
Ability to discontinue SOC, NCC-Sp, ceruloplasmin, 24-hour urinary copper and radiolabeled CuPET




Clinical trial initiated, anticipate initial clinical data in 2027


OBD = Optimal Biological Dose; NCC = Non-Ceruloplasmin-bound Copper; PD = Pharmacodynamics; LNP = Lipid Nanoparticle; SOC = Standard of Care; LTFU = Long-Term Follow-Up; RP3D = recommended phase 3 dose

We Plan to Leverage Platform Modularity to Rapidly Advance Prime Editors for a Majority of Wilson Disease Patients

prime_ medicine



IND = investigational new drug; CTA = clinical trial application; LNP = lipid nanoparticle; DC = development candidate; PMDA = Japan's Pharmaceuticals and Medical Devices Agency



Alpha-1 Antitrypsin Deficiency (AATD)

Advancing Prime Editors for AATD: Disease Overview

Disease Severity and Opportunity

- AATD is an inherited genetic disorder that causes low levels of AAT protein
- Low levels of AAT protein increases the risk of lung disease (emphysema)
- Patients are also at risk of liver disease (cirrhosis) caused by mutant protein aggregation
- Approximately 200,000 patients in the US and EU, ~10-15% of which are diagnosed today*

Unmet Need

- Many patients progress to liver failure or severe lung disease, requiring transplant
- Current standard of care includes chronic AAT augmentation therapy for lung disease; no approved curative therapies
- No approved treatments for liver disease

Human Biology


- Autosomal codominant disorder due to mutations in SERPINA1 gene
- Lung: lack of functional AAT leads to unrestricted neutrophil elastase activity, among other pathological changes (loss of function)
- Liver: defective AAT protein misfolding and accumulation (gain of function)



We believe Prime Editing is uniquely well-suited to correct mutant AAT protein to wild-type without the risk of bystander edits

AATD = Alpha-1 Antitrypsin Deficiency; A1AT = alpha-1 antitrypsin
*Prime Medicine estimate

AATD Program Objective: Normalize AAT Levels in PiZZ Genotype Patients to Healthy Human Levels




Program Goals

- Restore SERPINA1 gene to wild type, without bystander or other unwanted edits
- Increase M-AAT levels minimally above protective threshold (~11 µM), ideally into healthy human range (>20 µM)
- Maintain wild-type protein under endogenous control to protect patients during acute episodes (M-AAT levels rise 2-4x)
- Decreasing Z-AAT in the liver may potentially ameliorate the liver manifestations of AATD

*Taken from Vidal R, Blanco I, Casas F, *et al.* Arch Bronconeumol. 2006;42(12):645-59; ** MZ, SZ and ZZ genotype contain Pi*Z mutation; Z-AAT = mutant A1AT protein.

PM647 Efficiently Corrected the Mutation *In Vivo* Resulting in M-AAT Protein Restoration at Clinically Relevant Doses

prime_ medicine



M-AAT = healthy A1AT protein; Z-AAT = mutant A1AT protein; IND = investigational new drug; CTA = clinical trial application
*Performed by LC-MS; **Analysis at day 7 positive control = healthy human serum

PM647 Clinical Trial Overview

Trial Overview


Design
Phase 1/2, open-label

Population
Adults with PiZZ AATD: lung-only (Group A) or lung + liver / liver-only disease (Group B)

Treatment
One-time IV infusion of PM647a

Primary Endpoints
Safety, tolerability

Key Secondary Endpoints
Serum AAT thresholds and isoforms; pulmonary and liver measures



IND cleared for Phase 1/2 trial, anticipate initial clinical data in 2027

AATD = Alpha-1 Antitrypsin Deficiency; BAL = Bronchoalveolar Lavage; DLT = Dose-Limiting Toxicity; FIH = First-in-Human; MTD = Maximum Tolerated Dose; OBD = Optimal Biological Dose; RP3D = Recommended Phase 3 Dose; SRC = Safety Review Committee

Lung



Advancing Prime Editors for Cystic Fibrosis (CF), a Disease for Which There is No Curative Therapy

prime_ medicine

Prime Medicine's efforts in Cystic Fibrosis funded through multiple grants from the Cystic Fibrosis Foundation

Disease Severity and Opportunity

- Progressive, genetic disease that affects the lungs, pancreas and other organs, leading to premature death
- Impacts close to 40,000 people in the United States, ~1,000 new cases diagnosed each year


Unmet Need

- Existing treatment options include airway clearance, inhaled medicines, pancreatic enzyme supplements, fitness plans and CFTR modulators for patients with specific mutations
- No cure and existing treatments are ineffective for, or not tolerated by, approximately 15% of patients


Human Biology

- Autosomal recessive disorder caused by mutations in the CFTR gene, which cause CFTR protein to become dysfunctional
- Dysfunctional CFTR reduces chloride and bicarbonate transport to epithelial lumen

Healthy



Cystic Fibrosis




We believe Prime Editing-based approaches could eventually benefit the vast majority of people with cystic fibrosis.

CFTR = cystic fibrosis transmembrane conductance regulator


Prime Medicine has Made Significant Progress Developing Prime Editors for G542X Mutated Cystic Fibrosis

prime medicine

G542X In vitro Prime Editor in Primary HBEs



Phenotypic restoration of G542X mutated CFTR in differentiated ALI culture




Efforts towards LNP *in vivo* delivery to humanized mice and large animals ongoing

Parallel Prime Editing Approaches to CF: Hotspot and PASSIGE


Hotspot

Eight hotspot Prime Editors could address the "high unmet need" mutations; these same Prime Editors could address >93% of all CF patients



PASSIGE

Potential to address nearly all CF patients with a single super exon insertion strategy



Restoring CFTR function in Prime Edited cells under endogenous control

CF = cystic fibrosis; attP = complimentary recognition sequence for attB; SA = splice acceptor; 3' UTR = 3' untranslated region; *Exons in gray introns in black

Immunology and Oncology



Chronic Granulomatous Disease (CGD)

Advancing Prime Editor for CGD: Disease Overview

Rare genetic disease, characterized by defective neutrophil function

Disease Severity and Opportunity


- Serious life-threatening disease presents in childhood; life expectancy approximately 40 years
- Results in recurrent, life-threatening infections which are difficult to eradicate, leads to frequent hospitalizations
- Potentially deadly infections from normal exposures (e.g., gardening, swimming)

Unmet Need

- Current treatment options include
  - Lifelong anti-microbial therapy (frequently leading to antimicrobial resistance)
  - Allogenetic HSCT is the only curative option made complicated by GvHD, graft failure and limited availability (e.g., matched donor)

Human Biology


- p47phox is a cytosolic regulatory subunit of the NADPH oxidase complex
- Majority of p47phox CGD patients share single causative dinucleotide deletion (ΔGT)
- Defective NADPH oxidase renders neutrophils, monocytes and macrophages ineffective



Breakthrough Clinical Data with PM359 in CGD Provide Proof-of-Concept for Prime Editing as the Foundation for a New Class of Curative Therapies

prime_ medicine

Observed rapid engraftment, restored DHR positivity and improvement in inflammatory markers, with acceptable safety



- **Successful manufacturing** from single mobilizations
- **Tolerable myeloablative conditioning** at fully therapeutic exposures with expected adverse events (transitory mucositis, pancytopenia)
- **No serious adverse events** attributed to PM359
- **Rapid neutrophil and platelet engraftment** confirmed within 2-3 weeks post transplant, markedly faster than current benchmarks
- **Rapid recovery of NADPH oxidase activity**: ~3-4x therapeutic threshold by day 30, sustained out to six months post infusion
- **Both patients remain free of new CGD-related complications or significant intercurrent illness post-infusion;** patient 2 demonstrated improvement in inflammatory markers of CAC

Prime Medicine plans to submit a BLA following final regulatory alignment

*Source: CASGEVY label, median time to engraftment for neutrophils and platelets observed at days 27 and 35, respectively
Note: patient #1 was an 18 year old male, patient #2 was a 57 year old male
DHR = dihydrorhodamine, an assay to measure NADPH oxidase activity

Prime Medicine Has Not Observed Any Detectable Off-Target Editing, Large Deletions, or Translocations in Any Lead Program


Prime Medicine uses CRISPR-Cas9 editors as a positive control in off-target analyses


Examples from CGD program used to support IND/CTA filings


No off-target editing detected in healthy human donor CD34+ cells[1]

No large deletions or translocations observed in Prime-Edited LT-HSCs[2] vs. Cas-9 nuclease edited cells

No off-target edits detected with Prime Editing vs. Cas9








- **No** detectable double strand breakage
- **No** detectable off-target edits
- **No** detectable bystander edits
- **No** detectable deletions, chromosomal translocations or rearrangements

[1]Analysis of edited CD34+ cells from CGD program: Targeted *in vitro* Analysis of 550 potential off-target sites of off-target editing. [2]Data from *in vivo* analysis from mouse bone marrow harvested 16 weeks after engraftment was complete. [3]Cas9 nuclease-edited cells, generated by transfecting HEK293T with sgRNA targeting *NCF1* and SpCas9 mRNA.
CGD = chronic granulomatous disease; HSC = hematopoietic stem cell; IND = investigational new drug; CTA = clinical trial application

Ex-Vivo CAR-T



CAR-T: PASSIGE and Multiplex Prime Editing is the Foundation of Prime Medicine's Collaboration with BMS

prime_ medicine

Platform modularity has potential to accelerate development of additional CAR-T Programs

	Existing Limitations	Prime Editing Solution
Multiplex Engineering	✗ Low payload integration efficiency ✗ Constrained to limited number of knock-outs and limited single base pair changes	✓ **>80% integration** efficiency of CAR, aimed at TRAC locus to maintain **endogenous control** ✓ Capable of **multiple edits done safely**, each with a **full suite of functional modifications**
Safety	✗ Random or semi-random integration ✗ High rate of translocations / chromosomal abnormalities	✓ **Precise on-target** transgene integration ✓ Based on our extensive off-target evaluations in other settings, **there is the potential for no detectable off-target edits, translocations, or unintended structural abnormalities** in Prime-Edited CAR-T's
Manufacturing / Cost of Goods	✗ Dependence on viral components ✗ Complicated by multi-step engineering	✓ **Entirely non-viral** manufacturing process ✓ **Single-step** editing and integration

TRAC = T-cell receptor alpha constant; Data presented at ASH, December 2022, ASGCT, May 2023 and ASH, December 2023

Strategic License and Broad Collaboration Agreement with Bristol Myers Squibb (BMS) to Develop Prime Edited *ex Vivo* CAR-T Products

First broad, multi-target collaboration advancing Prime Editors for the treatment of complex oncology and autoimmune indications

prime medicine	**Leadership in Prime Editing; PASSIGE technology may enable one-step, non-viral, multi-kilobase-size editing approach with no double-stranded breaks**
Bristol Myers Squibb	**Global leader in cell therapy for hematology, immunology and oncology**

- $110 million upfront (including $55M equity investment)
- >$3.5 billion in potential milestones, including:
  - $185 million in preclinical milestones
  - $1.2 billion in development milestones
  - More than $2.1 billion in commercial milestones
  - Royalties on net sales
- Multiple targets in immunological diseases and cancer, beyond the genetic diseases in Prime Medicine's internal pipeline


Prime Medicine retains the ability to advance reagents designed under this collaboration in certain *ex vivo* (non-BMS targets) and all *in vivo* T cell and other cell therapy applications

Beyond Precisely Inserting a Chimeric Antigen Receptor, We Can Simultaneously and Efficiently Multiplex Edit CAR-T Cells


prime_ medicine

Prime Editors can be multiplexed to introduce multiple genomic modifications in CAR-T cells

High efficiency multiplex editing of B2M and TRAC



Maintained efficiency with five multiplex edits



Corporate



Our Strategy to Maximize the Broad Therapeutic Potential of Prime Editing

prime medicine

Within Our Core

Partner at the right time to fund, advance and commercialize our wholly owned pipeline programs (e.g., liver, lung)

CYSTIC FIBROSIS FOUNDATION

Funding accelerates the development of Prime Editors for Cystic Fibrosis

Outside Our Core

Form strategic partnerships to access expertise and expand into therapeutic areas beyond our near-term internal focus (e.g., cell therapy, CNS)

Bristol Myers Squibb

Developing Prime Edited CAR-T products leveraging PASSIGE and platform

Enabling Innovation

Access best-in-class enabling technologies to unlock the full potential of Prime Editing (e.g., delivery technologies)

By pairing our internal resources with strategic partners and best-in-class enabling technologies, we aim to accelerate platform development and extend the reach of Prime Editing

Prime Medicine is Leading the Next Generation of Gene Editing

prime_ medicine

Pipeline Positioned for Value Creation

- Wilson disease clinical trial underway; AATD IND cleared; initial clinical data from both anticipated in 2027
- Focused on programs in large genetic diseases, with clear path to value and multi billion-dollar opportunities
- CGD progressing towards BLA submission planned for the first half of 2027

Platform Modularity Oriented for Growth

- Fully integrated modular platform powers every program and drives leverage
- Proprietary modular delivery systems accelerate follow-on programs within target tissues
- New regulatory models pave way for platform-based approvals

Preeminent Editing Technology

- Permanently corrects genetic alterations, without causing double-strand breaks or bystander edits
- Potential to address approximately 90% of genetic diseases and opportunities in non-genetic diseases
- Prime Medicine's comprehensive IP portfolio covers any permutation of Prime Editing


Significant Partnerships and BD Potential

- BMS partnership to develop Prime Edited *ex vivo* CAR-T products
- Cystic Fibrosis Foundation relationship and funding to advance Prime Editors for Cystic Fibrosis
- Additional business development to accelerate and expand pipeline

Cash, cash equivalents, investments and restricted cash of $108.8M for 6/30/2026, cash runway into 2027

CGD = Chronic granulomatous disease; AATD = Alpha-1 Antitrypsin Deficiency; IND = investigational new drug; CTA = clinical trial application

Appendix



Prime Editing is Designed with a Wide Range of Genome Editing Capabilities

Flexibility to select right approach for each indication based on editing need

Prime Editing Approach	Small edits (e.g., all 12 bp swaps, 1-bp to 20-bp ins or del, combinations thereof)	Mid-sized edits (e.g., hotspot corrections, del up to 1-kb, ins up to 250 bp)	Large deletions (e.g., multi-kb repeat excision, exon del)	Large insertions or inversions (e.g., targeted multi-kb gene integration)
Short Flap Prime Editing	✓ +++			
Dual Flap Prime Editing	✓ ++	✓ +++	✓ +++	
Long Flap Prime Editing	✓ ++	✓ +++	✓ ++	
PASSIGE		✓ +	✓ +	✓ +++

✓ = capable of the edit


+/++/+++ = how fit Prime Medicine believes the technology is for making the edit, based on Prime Medicine's internal assessment

BP = base pair; KB = kilobase

PASSIGE Technology Enables Prime Editing to Insert Gene Sized Sequences Precisely, Potentially Addressing Large Markets

prime_ medicine

PASSIGE: Prime-Assisted Site-Specific Integrase Gene Editing:
One step non-viral multi-kilobase-size gene editing approach with no double-stranded breaks



Where we are working today:

- **Non-viral, multiplex-edited CAR-T therapies**
  BMS collaboration (e.g., oncology and autoimmune diseases)
- **Cystic Fibrosis**

Areas of opportunity:*

- **Targeted whole gene replacement for bone marrow diseases**
  (e.g., Hereditary anemias, such as Fanconi Anemia)
- **Correct inversion mutations**
  (e.g., Hemophilia A)
- **Targeted whole gene replacement for rare liver diseases**
  (e.g., Phenylketonuria, Tyrosinemia)
- ***In vivo* protein factory**
  (e.g., GLA enzyme for Fabry's disease)

*Not part of Prime Medicine's current pipeline